477
Participants
Start Date
November 6, 2013
Primary Completion Date
August 18, 2015
Study Completion Date
September 16, 2015
Vericiguat (BAY1021189) (1.25 mg)
1.25 mg BAY1021189 tablets
Vericiguat (BAY1021189) (5 mg)
5 mg BAY1021189 tablets
Placebo
New Taipei City
Kaohsiung City
Vienna
Budapest
Bruxelles - Brussel
Sofia
Geneva
Vienna
Sofia
Sofia
Sofia
Darlinghurst
Mol
Mechelen
Sankt Pölten
Linz
Redcliffe
Linz
Brisbane
Brisbane
Holbæk
Huy
Salzburg
Stara Zagora
Gilly
Lugano
Hobart
Bruges
Székesfehérvár
Burgas
Graz
Roeselare
Randers
Ghent
Aalborg
Taipei
Prague
Taipei
Athens
Chaïdári
Prague
Buffalo
Pittsburgh
Greifswald
Milan
Milan
Hamburg
Bergamo
Brescia
Pavia
Majadahonda
Charleston
El Palmar
Hanover
Macon
Toulouse
Fort Lauderdale
Pessac
Naples
Germantown
Santander
Valencia
Valencia
Münster
Detroit
Cologne
Arezzo
Iowa City
Milwaukee
Minneapolis
Ancona
Bad Homburg
Homburg
Bron
Rouen
Bad Krozingen
München
Fountain Valley
Erfurt
Singapore
Singapore
Singapore
Taoyuan District
Singapore
Tiberias
Afula
Haifa
Hadera
Petah Tikva
Tel Aviv
Zrifin
Rehovot
Ashkelon
Jerusalem
Chicago
New Orleans
Jackson
Newark
Nashville
Toronto
Montreal
Montreal
Saint-Jean-sur-Richelieu
Sherbrooke
Québec
Kroměříž
Prague
Prague
Nea Ionia / Athens
Kistarcsa
Iizuka
Himeji
Higashiibaraki
Kanazawa
Takamatsu
Sagamihara
Yokohama
Yokosuka
Uji
Naha
Sakai
Takatsuki
Komatsushimachō
Meguro-ku
Minato-ku
Fukui
Hiroshima
Kumamoto
Nagasaki
Osaka
Tokushima
Toyama
Amsterdam
Heerenveen
Leeuwarden
Sneek
Bialystok
Krakow
Krakow
Lodz
Lodz
Olsztyn
Poznan
Szczecin
Almada
Lisbon
Lisbon
Lisbon
Seoul
Barcelona
Barcelona
Helsingborg
Karlstad
Linköping
Örebro
Stockholm
Chesterfield
Stevenage
Lead Sponsor
Bayer
INDUSTRY